Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner on other assets.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner on other assets.